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In breast cancer, the presence of tumor-in-
filtrating lymphocytes (TILs) is reported to 
confer a survival advantage (Schmidt et al., 
2018; Heimes et al., 2017a, b). Usually, in-
creased infiltration with T- or B-cells is asso-
ciated with better prognosis (Schmidt et al., 
2008; Chen et al., 2012; Godoy et al., 2014), 
and it has also been associated with better re-
sponse to neoadjuvant chemotherapy 
(Schmidt et al., 2012; Sota et al., 2014). Fac-
tors related with an immunosuppressive mi-
croenvironment, such as elevated adenosine 
levels and high expression of the ectonucleo-
tidase CD73 (Leone and Emens, 2018), have 
contrarily been shown to be associated with 
worse prognosis in breast cancer (Jiang et al., 
2018). It has also been reported that tumors 
can suppress the anti-cancer immune re-
sponse by the regulation of lactic acid produc-
tion, and maintenance of a relatively low pH 
in the tumor microenvironment (Choi et al., 
2013), further stressing the importance of im-
mune regulatory factors in cancer. 
Recently, immune checkpoint inhibitors, 
targeting CTLA-4 and the PD-1/PD-L1 axis 
have been shown to generate long-lasting re-
sponses in several cancer types (Pennock and 
Chow, 2015). For instance, CTLA-4 is known 
to abrogate the activated T-cell response, and 
antagonizing this mechanism represents an 
emerging anti-cancer strategy (Sharma and 
Allison, 2015; Melero et al., 2014). Many 
breast cancers exhibit relatively low T-cell in-
filtration together with a low neoantigen bur-
den, as well as inadequate T-cell priming and 
expansion; thus they have been referred to as 
“immunologically cold" (Vonderheide et al., 
2017). Therefore, activation and expansion of 
tumor-specific T-cells represents a major fo-
cus in cancer research (Xu et al., 2013; 
Sharma and Allison, 2015; Melero et al., 
2014; Le et al., 2013; Cheever et al., 2009). 
Such approaches might be of particular inter-
est for triple-negative breast cancers, a sub-
type where currently few treatment options 
are available in addition to chemotherapy, and 
that has been reported to have higher levels of 
TILs compared with other subtypes (Vonder-
heide et al., 2017; Katz and Alsharedi, 2017). 
In this field, Lina Liu and colleagues re-
cently published an interesting study in which 
they induced a cytotoxic T-lymphocyte re-
sponse in a mouse model of triple negative 
breast cancer (Liu et al., 2018). The authors 
used nanoparticles as carriers to deliver 
mRNA encoding the transmembrane protein 
MUC1 to dendritic cells in lymph nodes. Car-
cinomas of the breast, ovary, colon, rectum, 
pancreas and prostate are known to overex-
press MUC1. Administration of MUC1 
mRNA loaded nanoparticles clearly reduced 
tumor growth in the mice. Combined admin-
istration of MUC1 mRNA plus an anti-
CTLA-4 antibody additionally reduced tumor 
size compared to treatment with MUC1 
mRNA alone. Liu and colleagues are to be 
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congratulated for their interesting results. Fu-
ture research will show whether the MVL1 
mRNA nano-vaccine will be successful in 
translational studies.  
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